Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Prostate Cancer

  Free Subscription


22.07.2024

6 BJU Int
2 BMC Urol
1 Br J Cancer
3 Cancer
1 Eur Urol
1 Int J Oncol
2 Int J Radiat Oncol Biol Phys
3 Int J Urol
1 J Nucl Med
1 J Urol
1 Mod Pathol
3 Prostate
2 Radiology
1 Urology


   Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    BJU Int

  1. NG KL, Giona S, Barber N
    Feasibility of Aquablation prostate surgery performed as day cases.
    BJU Int. 2024;134:185-186.
    PubMed        

  2. ABUELNAGA M, Gendy R, Yao M, Phelan C, et al
    Impact of definitions on continence outcomes in a series of 1000 robot-assisted radical prostatectomies, time for an internationally agreed definition?
    BJU Int. 2024;134:197-200.
    PubMed        

  3. FANKHAUSER CD, Malkmus C, Aschwanden F, Baumeister P, et al
    'Igloo' technique for robot-assisted radical prostatectomy - maximum nerve sparing for early recovery of continence and sexual function.
    BJU Int. 2024;134:307-311.
    PubMed        

  4. JACEWICZ M, Rud E, Lauritzen P, Baco E, et al
    Non-infectious adverse events of transperineal prostate biopsies performed under local anaesthesia.
    BJU Int. 2024;134:300-306.
    PubMed         Abstract available

  5. MAURER J, Ambrosini F, Chen Y, Schroeder S, et al
    Acupuncture: a strategy for pain management among patients with prostate cancer - authors' reply.
    BJU Int. 2024 Jul 16. doi: 10.1111/bju.16468.
    PubMed        

  6. YANG J, Xiong X, Wei Q, Yang L, et al
    Acupuncture: a promising adjuvant strategy for pain management among the patients with prostate cancer.
    BJU Int. 2024 Jul 17. doi: 10.1111/bju.16467.
    PubMed        


    BMC Urol

  7. SONG Z, Xu S, Gu X, Feng Q, et al
    LncRNA PITPNA-AS1 mediates the diagnostic potential of miR-129-5p in prostate cancer.
    BMC Urol. 2024;24:146.
    PubMed         Abstract available

  8. CHENG L, Li S, Jiang D, Sun R, et al
    Decreased levels of PTCSC3 promote the deterioration of prostate cancer and affect the prognostic outcome of patients through sponge miR-182-5p.
    BMC Urol. 2024;24:144.
    PubMed         Abstract available


    Br J Cancer

  9. LIN BB, Huang Q, Yan B, Liu M, et al
    An 18-gene signature of recurrence-associated endothelial cells predicts tumor progression and castration resistance in prostate cancer.
    Br J Cancer. 2024 Jul 12. doi: 10.1038/s41416-024-02761.
    PubMed         Abstract available


    Cancer

  10. MORRIS MJ, de Bono J, Nagarajah J, Sartor O, et al
    Correlation analyses of radiographic progression-free survival with clinical and health-related quality of life outcomes in metastatic castration-resistant prostate cancer: Analysis of the phase 3 VISION trial.
    Cancer. 2024 Jun 21. doi: 10.1002/cncr.35438.
    PubMed         Abstract available

  11. SANYAL C, Ragavan MV
    Beyond the PSA: The hidden costs of screening in prostate cancer.
    Cancer. 2024 Jul 16. doi: 10.1002/cncr.35474.
    PubMed        

  12. SRIVASTAVA A, Tilea A, Kim DD, Dalton VK, et al
    Out-of-pocket costs for diagnostic testing following abnormal prostate cancer screening among privately insured men.
    Cancer. 2024 Jul 15. doi: 10.1002/cncr.35392.
    PubMed         Abstract available


    Eur Urol

  13. SPRATT DE, Liu VYT, Jia AY, Royce TJ, et al
    Meta-analysis of Individual Patient-level Data for a Multimodal Artificial Intelligence Biomarker in High-risk Prostate Cancer: Results from Six NRG/RTOG Phase 3 Randomized Trials.
    Eur Urol. 2024 Jul 17:S0302-2838(24)02454-0. doi: 10.1016/j.eururo.2024.
    PubMed        


    Int J Oncol

  14. ZHENG XM, Zhang P, Liu MH, Chen P, et al
    [Retracted] MicroRNA?30e inhibits adhesion, migration, invasion and cell cycle progression of prostate cancer cells via inhibition of the activation of the MAPK signaling pathway by downregulating CHRM3.
    Int J Oncol. 2024;65:82.
    PubMed         Abstract available


    Int J Radiat Oncol Biol Phys

  15. FREDMAN E, Moore A, Icht O, Tschernichovsky R, et al
    Acute toxicity and early PSA response after two-fraction stereotactic radiotherapy for localized prostate cancer using peri-rectal spacing - Initial report of the SABR-Dual trial.
    Int J Radiat Oncol Biol Phys. 2024 Jul 11:S0360-3016(24)02947.
    PubMed         Abstract available

  16. ROY S, MacRae R, Grimes S, Malone J, et al
    Helical Tomotherapy versus Three-Dimensional Conformal Radiotherapy in High Risk Prostate Cancer: A Phase III Randomized Controlled Trial.
    Int J Radiat Oncol Biol Phys. 2024 Jul 13:S0360-3016(24)02957.
    PubMed         Abstract available


    Int J Urol

  17. SUN Q, Du K, Sun S, Liu Y, et al
    Local treatment benefits patients with oligometastatic prostate cancer: A systematic review and meta-analysis.
    Int J Urol. 2024 Jul 16. doi: 10.1111/iju.15540.
    PubMed         Abstract available

  18. AIZAWA R, Ishikawa H, Kato M, Shimizu S, et al
    Significance of androgen-deprivation therapy for intermediate- and high-risk prostate cancer treated with high-dose radiotherapy: A literature review.
    Int J Urol. 2024 Jul 17. doi: 10.1111/iju.15535.
    PubMed         Abstract available

  19. URABE F, Muramoto K, Yanagisawa T, Fukuokaya W, et al
    Changes in the treatment landscape of metastatic hormone-sensitive prostate cancer following approval of upfront androgen receptor signaling inhibitors: A multicenter study.
    Int J Urol. 2024 Jul 19. doi: 10.1111/iju.15546.
    PubMed         Abstract available


    J Nucl Med

  20. BASACO BERNABEU T, Mansi R, Del Pozzo L, Zanger S, et al
    (61)Cu-PSMA-Targeted PET for Prostate Cancer: From Radiotracer Development to First-in-Human Imaging.
    J Nucl Med. 2024 Jul 18:jnumed.123.267126. doi: 10.2967/jnumed.123.267126.
    PubMed         Abstract available


    J Urol

  21. SZABO RJ
    Letter: Complications Following Transrectal and Transperineal Prostate Biopsy: Results of the ProBE-PC Randomized Clinical Trial.
    J Urol. 2024;211:801-802.
    PubMed        


    Mod Pathol

  22. HARDER C, Pryalukhin A, Quaas A, Eich ML, et al
    Enhancing Prostate Cancer Diagnosis: AI-Driven Virtual Biopsy for Optimal MRI-Targeted Biopsy Approach and Gleason Grading Strategy.
    Mod Pathol. 2024 Jul 17:100564. doi: 10.1016/j.modpat.2024.100564.
    PubMed         Abstract available


    Prostate

  23. FRIEDRICH NA, Gu L, Waller J, De Hoedt AM, et al
    Real-world evidence of (18)F-fluciclovine Positron emission tomography/computed tomography performance for recurrent prostate cancer in the Veterans Affairs Health System.
    Prostate. 2024 Jul 19. doi: 10.1002/pros.24770.
    PubMed         Abstract available

  24. MIYAHIRA AK, Soule HR
    The 30th Annual Prostate Cancer Foundation Scientific Retreat Report.
    Prostate. 2024 Jul 17. doi: 10.1002/pros.24768.
    PubMed         Abstract available

  25. SUTERA P, Kim J, Kumar R, Deek RA, et al
    PIK3/Akt/mTOR pathway alterations in metastatic castration-sensitive prostate cancer.
    Prostate. 2024 Jul 17. doi: 10.1002/pros.24765.
    PubMed         Abstract available


    Radiology

  26. GHAI S, Klotz L, Pond GR, Kebabdjian M, et al
    Comparison of Multiparametric MRI-targeted and Systematic Biopsies for Detection of Cribriform and Intraductal Carcinoma Prostate Cancer.
    Radiology. 2024;312:e231948.
    PubMed         Abstract available

  27. SCIALPI M, Martorana E
    Apparent Diffusion Coefficient and Biopsy in Detecting Cribriform and Intraductal Carcinoma Prostate Cancer.
    Radiology. 2024;312:e241043.
    PubMed        


    Urology

  28. MILLOT J, Arenas-Gallo C, Shoag JE
    Reply to Letter to the Editor on "Major Complications and Adverse Events Related to use of SpaceOAR Hydrogel for Prostate Cancer Radiotherapy".
    Urology. 2024 Jul 11:S0090-4295(24)00561-2. doi: 10.1016/j.urology.2024.
    PubMed        


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.